What do systematic reviews say?

Secukinumab vs placebo

Secukinumab probably leads to higher proportion of participants with a 50% reduction in disease severity compared with placebo (moderate certainty).

• Interventions for chronic palmoplantar pustulosis 2020 · Cochrane Headline outcomes only
  RR 1.55 [1.02, 2.35]
  1 study · 157 participants
  Moderate